

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: August 12, 2025
PDL Changes Effective Date: October 1, 2025



The following changes will be made to the Preferred Drug List (PDL), effective October 1, 2025, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
Select Contraceptives (Oral Contraceptives)	Averi (ethinyl estradiol, desogestrel and iron)
Select Contraceptives (Oral Contraceptives)	Meleya (norethindrone)
Select Contraceptives (Oral Contraceptives)	Rosyrah (ethinyl estradiol and levonorgestrel)
NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Alzheimer's Agents, Cholinesterase Inhibitors	Zunveyi (benzgalantamine)
Antiretrovirals, Capsid Inhibitors	Yeztugo (lenacapavir)
Antineoplastics – Selected Systemic Enzyme Inhibitors	nilotinib
Bone Resorption Suppression and Related Agents, Others	Jubbonti (denosumab-bbdz)
Bone Resorption Suppression and Related Agents, Others	Osenvelt (denosumab-bmwo)
Bone Resorption Suppression and Related Agents, Others	Stoboclo (denosumab-bmwo)
Bone Resorption Suppression and Related Agents, Others	Wyost (denosumab-bbdz)
Bone Resorption Suppression and Related Agents, Others	Bonsity (teriparatide)
Colony Stimulating Factors	Ryzneuta (efbemalenograstim alfa-vuxw)
Cytokine and CAM Antagonists	Legselvi (deuruxolitinib)
Cytokine and CAM Antagonists	Imuldosa (ustekinumab-srlf)
Factor Deficiency Products, Other Hemophilia Products	Qfitlia (fitusiran)
Hereditary Angioedema Treatments	Andembry (garadacimab-gxii)
Platelet Aggregation Inhibitors	ticagrelor
Pulmonary Antihypertensive Agents, Prostacyclins	Yutrepia (treprostinil)